Oregovomab
As of the edition of 20 October 2026, Oregovomab is an antibody: in active development; acts on MUC16.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 16, 7 stopped early
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Oregovomab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MUC16 | Mucin-16 | Q8WXI7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 12 | 2 | 3 | 4 |
| Phase 3 | 2 | 0 | 1 | 1 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AltaRex | Lead sponsor of trials | 1998 to now |
| Unither Pharmaceuticals | Lead sponsor of trials | 2000 to now |
| Quest PharmaTech | Lead sponsor of trials | 2012 to now |
| CanariaBio | Lead sponsor of trials | 2017 to now |